Risk Factors for Mortality and Antimicrobial Regimens in Pediatric Intensive Care Unit Patients with Carbapenem-Resistant Enterobacteriaceae Infections: A Six-Year Retrospective Study

References

• Potter RF, D’Souza AW, Dantas G. The rapid spread of carbapenem-resistant Enterobacteriaceae. Drug Resist Updat. 2016;29:30–46. doi:10.1016/j.drup.2016.09.002
   PubMed Web of Science ®Google Scholar
• Bogan C, Kaye KS, Chopra T, et al. Outcomes of carbapenem-resistant Enterobacteriaceae isolation: matched analysis. Am J Infect Control. 2014;42:612–620. doi:10.1016/j.ajic.2014.02.013
   Web of Science ®Google Scholar
• Almangour TA, Ghonem L, Aljabri A, et al. Ceftazidime-avibactam versus colistin for the treatment of infections due to carbapenem-resistant Enterobacterales: a multicenter cohort study. Infect Drug Resist. 2022;15:211–221. doi:10.2147/IDR.S349004
   PubMed Web of Science ®Google Scholar
• Zhou R, Fang X, Zhang J, et al. Impact of carbapenem resistance on mortality in patients infected with Enterobacteriaceae: a systematic review and meta-analysis. BMJ Open. 2021;11:e054971. doi:10.1136/bmjopen-2021-054971
   PubMed Web of Science ®Google Scholar
• Chen L, Han X, Li Y, et al. Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant enterobacterales. Antimicrob Agents Chemother. 2021;65:e0069821. doi:10.1128/AAC.00698-21
   Web of Science ®Google Scholar
• Logan LK, Renschler JP, Gandra S, et al. Carbapenem-resistant Enterobacteriaceae in children, United States, 1999–2012. Emerg Infect Dis. 2015;21:2014–2021. doi:10.3201/eid2111.150548
   Web of Science ®Google Scholar
• Montagnani C, Prato M, Scolfaro C, et al. Carbapenem-resistant Enterobacteriaceae infections in children: an Italian retrospective multicenter study. Pediatr Infect Dis J. 2016;35:862–868. doi:10.1097/INF.0000000000001188
   PubMed Web of Science ®Google Scholar
• Nabarro LEB, Shankar C, Pragasam AK, et al. Clinical and bacterial risk factors for mortality in children with carbapenem-resistant Enterobacteriaceae bloodstream infections in India. Pediatr Infect Dis J. 2017;36:e161–e166. doi:10.1097/INF.0000000000001499
   PubMed Web of Science ®Google Scholar
• Zhou C, Jin L, Wang Q, et al. Bloodstream infections caused by carbapenem-resistant Enterobacterales: risk factors for mortality, antimicrobial therapy and treatment outcomes from a prospective multicenter study. Infect Drug Resist. 2021;14:731–742. doi:10.2147/IDR.S294282
   PubMed Web of Science ®Google Scholar
• Li C, Li Y, Zhao Z, et al. Treatment options and clinical outcomes for carbapenem-resistant Enterobacteriaceae bloodstream infection in a Chinese university hospital. J Infect Public Health. 2019;12(1):26–31. doi:10.1016/j.jiph.2018.08.002
   PubMed Web of Science ®Google Scholar
• David S, Reuter S, Harris SR, et al. Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread. Nat Microbiol. 2019;4:1919–1929. doi:10.1038/s41564-019-0492-8
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Andini R, Zampino R. Management of carbapenem-resistant Enterobacteriaceae infections. Clin Microbiol Infect. 2019;25:943–950. doi:10.1016/j.cmi.2019.04.013
   PubMed Web of Science ®Google Scholar
• Patel K, Goldman JL. Safety concerns surrounding quinolone use in children. J Clin Pharmacol. 2016;56:1060–1075. doi:10.1002/jcph.715
   PubMed Web of Science ®Google Scholar
• Germovsek E, Barker CI, Sharland M. What do I need to know about aminoglycoside antibiotics? Arch Dis Child Educ Pract Ed. 2017;102:89–93. doi:10.1136/archdischild-2015-309069
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 28th ed. Clinical and Laboratory Standards Institute; 2018.
   Google Scholar
• European Committee on Antimicrobial Susceptibility Testing. Breakpoint Table for Interpretation of MICs and Zone Diameters, Version 9.0. Edition. European Committee on Antimicrobial Susceptibility Testing; 2019.
   Google Scholar
• Wang H, Yu YS, Wang MG, et al. Expert consensus on the operating procedures for tigecycline in vitro susceptibility testing. Chin J Lab Med. 2013;36:584–587.
   Google Scholar
• Watson RS, Choong K, Colville G, et al. Life after critical illness in children-toward an understanding of pediatric post-intensive care syndrome. J Pediatrics. 2018;198:16–24. doi:10.1016/j.jpeds.2017.12.084
   Web of Science ®Google Scholar
• Straney L, Clements A, Parslow RC, et al. Paediatric index of mortality 3: an updated model for predicting mortality in pediatric intensive care. Pediatr Crit Care Med. 2013;14:673–681. doi:10.1097/PCC.0b013e31829760cf
   PubMed Web of Science ®Google Scholar
• Haytoglu Z, Gundeslioglu OO, Yildizdas D, et al. Carbapenem and colistin resistance in children with Enterobacteriaceae infections. Turk J Pediatr. 2020;62:778–786. doi:10.24953/turkjped.2020.05.009
   Web of Science ®Google Scholar
• Gemke RJ, van Vught J. Scoring systems in pediatric intensive care: PRISM III versus PIM. Intensive Care Med. 2002;28:204–207. doi:10.1007/s00134-001-1185-2
   PubMed Web of Science ®Google Scholar
• Zhang LD, Huang HM, Cheng YC, et al. Predictive value of four pediatric scores of critical illness and mortality on evaluating mortality risk in pediatric critical patients. Chin Crit Care Med. 2018;30:51–56. doi:10.3760/cma.j.issn.2095-4352.2018.01.010
   Google Scholar
• Lee OJ, Jung M, Kim M, et al. Validation of the pediatric index of mortality 3 in a single pediatric intensive care unit in Korea. J Korean Med Sci. 2017;32:365–370. doi:10.3346/jkms.2017.32.2.365
   Web of Science ®Google Scholar
• Vincent JL, Russell JA, Jacob M, et al. Albumin administration in the acutely ill: what is new and where next? Crit Care. 2014;18:231. doi:10.1186/cc13991
   PubMed Web of Science ®Google Scholar
• Bar-Yoseph H, Cohen N, Korytny A, et al. Risk factors for mortality among carbapenem-resistant Enterobacteriaceae carriers with focus on immunosuppression. J Infect. 2019;78:101–105. doi:10.1016/j.jinf.2018.10.003
   Web of Science ®Google Scholar
• Tamma PD, Gerber JS, Hayes M, et al. Treatment of carbapenem-resistant Enterobacteriaceae infections in children. J Pediat Inf Dis Soc. 2020;9:56–66. doi:10.1093/jpids/piz085
   Web of Science ®Google Scholar
• Sahbudak Bal Z, Kamit Can F, Yazici P, et al. The evaluation of safety and efficacy of colistin use in pediatric intensive care unit: results from two reference hospitals and review of literature. J Infect Chemother. 2018;24:370–375. doi:10.1016/j.jiac.2017.12.017
   Web of Science ®Google Scholar
• Nakwan N, Chokephaibulkit K, Imberti R. The use of colistin for the treatment of multidrug-resistant Gram-negative infections in neonates and infants: a review of the literature. Pediatr Infect Dis J. 2019;38:1107–1112. doi:10.1097/INF.0000000000002448
   PubMed Web of Science ®Google Scholar
• van Duin D, Lok JJ, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis. 2018;66:163–171. doi:10.1093/cid/cix783
   PubMed Web of Science ®Google Scholar
• Hakeam HA, Alsahli H, Albabtain L, et al. Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia. Int J Infect Dis. 2021;109:1–7. doi:10.1016/j.ijid.2021.05.079
   PubMed Web of Science ®Google Scholar
• Castanheira M, Rhomberg PR, Flamm RK, et al. Effect of the beta-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2016;60:5454–5458. doi:10.1128/AAC.00711-16
   PubMed Web of Science ®Google Scholar
• Fu B, Yin D, Sun C, et al. Clonal and horizontal transmission of blaNDM among Klebsiella pneumoniae in children’s intensive care units. Microbiol Spectr. 2022;10:e0157421. doi:10.1128/spectrum.01574-21
   Web of Science ®Google Scholar